Merck Serono's Erbitux now a standard-of-care for confirmed KRAS wild-type metastatic colorectal cancer, news study show
Merck Serono, a division of German drug major Merck KGaA, says that survey results published at this year's American Society of Clinical Oncology (ASCO) annual meeting reveal that Erbitux (cetuximab) has become a standard of care for confirmed KRAS wild-type metastatic colorectal cancer (mCRC).
In addition, the number of patients being KRAS tested to determine if they could benefit from a personalized therapy, such as Erbitux, has leapt from 2.5% in 2008 to 42% in early 2009. These figures highlight a dramatic change in the practices of physicians involved in the management of mCRC, who are increasingly using the KRAS test to enable them to provide patients with personalized therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze